A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in adult subjects with active systemic lupus erythematosus.

First Posted May, 2017. Last Updated August, 2021

Study Status: Active, Not Recruiting

To Learn More Contact
Associate Director Clinical Trial Disclosure at 1-888-260-1599 or clinicaltrialdisclosure@celgene.com
ClinicalTrials.gov identifier: NCT03161483